NASDAQ:AIMT Aimmune Therapeutics (AIMT) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free AIMT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$34.49▼$34.4950-Day Range$34.30▼$34.5952-Week Range$10.09▼$37.00VolumeN/AAverage Volume1.71 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aimmune Therapeutics alerts: Email Address Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. About Aimmune Therapeutics Stock (NASDAQ:AIMT)Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Read More Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. AIMT Stock News HeadlinesJune 30, 2022 | finance.yahoo.comAimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022November 12, 2021 | financialpost.comAimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital MeetingJune 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.October 26, 2021 | finance.yahoo.comAimmune Closes Enrolment in Phase III Peanut Allergy StudyAugust 4, 2021 | ca.finance.yahoo.comAimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut AllergySee More Headlines Receive AIMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2020Today6/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AIMT CUSIPN/A CIK1631650 Webwww.aimmune.com Phone650-614-5220FaxN/AEmployees228Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-248,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-164.99% Return on Assets-89.50% Debt Debt-to-Equity Ratio0.73 Current Ratio7.53 Quick Ratio7.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.66 per share Price / Book20.78Miscellaneous Outstanding Shares65,450,000Free FloatN/AMarket Cap$2.26 billion OptionableOptionable Beta1.76 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Jayson Donald Alexander Dallas (Age 51)Pres, CEO & Director Mr. Eric H. Bjerkholt (Age 59)Chief Financial Officer Mr. Douglas T. Sheehy (Age 52)Gen. Counsel & Sec. Dr. Stephen George Dilly (Age 59)Special Advisor Dr. Daniel C. Adelman (Age 62)Chief Medical Officer Key CompetitorsRa PharmaceuticalsNASDAQ:RARXHarmony BiosciencesNASDAQ:HRMYKura OncologyNASDAQ:KURATaro Pharmaceutical IndustriesNYSE:TAROXencorNASDAQ:XNCRView All Competitors AIMT Stock Analysis - Frequently Asked Questions How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share for the quarter, hitting the consensus estimate of ($1.06). What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Block (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU). When did Aimmune Therapeutics IPO? Aimmune Therapeutics (AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO. This page (NASDAQ:AIMT) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aimmune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.